Michal Mrug, M.D.
Dr. Mrug is a Professor of Medicine in the Division of Nephrology at the University of Alabama at Birmingham (UAB). Recognized as one of “Top Doctors” by Castle Connolly Medical Ltd, he directs the UAB PKD Clinics and has overseen clinical PKD research activities at UAB since 2009. This includes the CRISP study, an NIH-funded collaborative effort between Emory University, University of Kansas, Mayo Clinic, UAB and University of Pittsburgh that has led to numerous seminal discoveries. He also coordinated the REPRISE clinical trial for UAB; outcomes of this study played a crucial role in the FDA approval of tolvaptan as the first treatment for ADPKD. Dr. Mrug’s clinical research is centered on the development of statistical models for identification of ADPKD patients that may benefit most from therapeutic interventions. His basic research is focused on the discovery of molecular pathways that modulate PKD progression. He also directs the Therapeutics Development and Screening Resource, one of four cores within the UAB Childhood Cystic Kidney Disease Core Center. This Center, together with PKD Centers at the University of Kansas and University of Maryland, form the NIH-funded U54 PKD-Research Consortium.